Wellington Management Group LLP Has $6.76 Million Holdings in Enliven Therapeutics, Inc. $ELVN

Wellington Management Group LLP lessened its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 11.3% in the second quarter, Holdings Channel.com reports. The institutional investor owned 133,143 shares of the company’s stock after selling 16,983 shares during the period. Wellington Management Group LLP’s holdings in Enliven Therapeutics were worth $6,757,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ELVN. KBC Group NV bought a new position in shares of Enliven Therapeutics in the 1st quarter worth about $38,000. State of Wyoming acquired a new position in shares of Enliven Therapeutics in the 2nd quarter valued at about $96,000. FNY Investment Advisers LLC bought a new stake in shares of Enliven Therapeutics during the 2nd quarter valued at about $126,000. BNP Paribas Financial Markets boosted its position in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares in the last quarter. Finally, Quantbot Technologies LP grew its stake in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

ELVN has been the subject of a number of research analyst reports. Barclays began coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Guggenheim lowered their price objective on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. William Blair assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday, August 18th. They set an “outperform” rating on the stock. Finally, HC Wainwright lifted their price target on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Enliven Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Enliven Therapeutics Price Performance

NASDAQ ELVN opened at $59.37 on Wednesday. The firm has a market cap of $4.35 billion, a price-to-earnings ratio of -35.55 and a beta of 0.30. Enliven Therapeutics, Inc. has a 1 year low of $14.78 and a 1 year high of $62.32. The company has a fifty day moving average price of $56.00 and a 200-day moving average price of $44.77.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.69 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $58.58, for a total transaction of $352,534.44. Following the completion of the sale, the chief financial officer directly owned 40,036 shares of the company’s stock, valued at $2,345,308.88. This trade represents a 13.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction on Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the sale, the director owned 41,884 shares in the company, valued at $2,114,723.16. The trade was a 19.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 186,849 shares of company stock worth $10,998,857. 3.00% of the stock is owned by company insiders.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.